Durable Responses With IL-15 Superagonist in Early Bladder Cancer
The use of the IL-15RAFC superagonist N-803 with intravesical bacillus Calmette-Guérin (BCG) resulted in high and more durable response rates in patients with non-muscle invasive bladder cancer (NMIBC) carcinoma in situ who were unresponsive to BCG, a phase II/III study found. Of the 81 patients included in the analysis, 58 achieved a complete response at […]